Parkinson’s Disease Treatment Market - By Drug Class (Levodopa/carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics, Other Drugs) By Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies) By Patient Care Setting (Hospitals, Clinics) By Region (North America, Europe, Asia, Rest of the World) - Industry Analysis, Opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 185
Status: Published
Report Code: ARI100725
The symptoms of this disease include rigidity, tremor, bradykinesia and postural instability. The global Parkinson’s disease drug market has witnessed remarkable growth in recent years owing to a large patient pool and increased diagnosis rates. According to the Parkinson's disease Foundation, there are about 10 million people suffering from Parkinson’s disease globally. Parkinson’s, in terms of its presence, has a higher frequency in the developed countries. In the United States (U.S.), around 60,000 new cases are diagnosed with Parkinson’s, each year. Parkinson’s disease is an idiopathic disease occurring due to unknown causes. Presently, only symptomatic drug treatments are available in the market. Moreover, these symptoms are diagnosed at later stages when most of the dopamine producing cells have lost their function. This scenario indicates an impending need for innovative drugs. Rising old age population and higher incidences of neurodegenerative diseases are two significant factors that drive the growth of this market. Moreover, increasing R&D investment and number of drugs in the pipeline are further expected to fuel the market growth. However, high cost of treatment and lack of expertise for early diagnosis is likely to curtail the market growth.
Latest developments in Parkinson’s disease treatment, for instance, combination treatments to prolong the action of unremitting dopaminergic stimulation medicines, support for neurostimulation tools, neuroprotective treatment to slow down prediction of a disease, neural transplantation and gene therapy, and so on, are anticipated to bring huge development in global Parkinson’s disease treatment market in the coming future. In addition, growing aging inhabitants, the occurrence of Parkinsonism across the globe are the major aspects propelling the demand and requirement for the global Parkinson’s disease treatment market. Also, increasing old age inhabitants and higher occurrences of the neurodegenerative syndrome are two important aspects that are likely to fuel the development of the global Parkinson’s disease treatment market. In addition, growing R&D venture and a number of medicines in the pipeline are further projected to propel the market development. On the other hand, high expenditure of treatment and short of proficiency for early diagnosis is anticipated to curtail the market development.
Key players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddy’s (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India), Strides (India), 1 A Pharma (India), and Upsher-Smith (US).
Analyst Commentary
Rising geriatric population and government funding for research on Parkinson’s disease are the driving factors for this market.
On the basis of drug class, the carbidopa/levodopa segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to the potency of the drug.
By distribution channel, the hospital pharmacies segment accounted for the largest share of the market. Increasing number of patient visits to the hospital due to the availability of diagnostic laboratories and presence of skilled neurologists are driving the growth of hospital pharmacies segment.
On the basis of patient care setting, hospitals are expected to account for the largest share of the market. Robust health infrastructure and presence of skilled neurologists are the driving factors for hospital segment.
Segmentation
The Parkinson’s disease treatment market is segmented on the basis of drug class, distribution channel, patient care setting, and region. On the basis of drug class, the market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. On the basis of patient care setting, the Parkinson’s disease treatment market is segmented into hospitals and clinics. By distribution channel, the market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies
Regional Analysis
By region, the Parkinson’s disease treatment market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by Europe, followed by North America; however, the Asian region is expected to witness the highest growth during the forecast period. Asia is expected to witness the highest CAGR, with the growth in this market centered at Japan, China, and India. The increasing number of generic drug manufacturers and rising aging populaion across are key factors driving the market in Asia. However, availability of alternative treatments is going to restrain this market
Europe is anticipated to achieve the largest share of the global Parkinson’s disease treatment market, which is likely to be followed by North America with a considerable market share. High knowledge about the treatment, augment in expenditure for R&D, favorable medicinal reimbursement regulations and policies, the high occurrence of Parkinson’s disease, the quickly increasing geriatric populace, and potential medical pipeline products are likely to contribute to the major share of Europe in the global Parkinson’s disease treatment market. The global Parkinson’s disease treatment market in the Asia Pacific is projected to develop at a reasonable rate. The most important market share of the global Parkinson’s disease treatment market is likely to be captured by China and Japan in the Asia Pacific, mainly owing to the large population of elderly people who are affected with Parkinson’s ailment in these countries.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Component
2.3.1. Secondary Component
2.3.1.1. Preliminary data mining
2.3.2. Primary Component
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Parkinson’s disease Treatment Market
Chapter 5. Global Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
5.1. Global Parkinson’s disease Treatment Market Share, By Drug Class, 2015 - 2027 (USD Million)
5.1.1. Carbidopa/levodopa
5.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Dopamine receptor agonists
5.1.2.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. MAO-inhibitors
5.1.3.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.4. Others
5.1.4.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.4.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027(USD Million)
6.1. Global Parkinson’s disease Treatment Market Share, By Distribution Channel, 2015 - 2027 (USD Million)
6.1.1. Hospital pharmacies
6.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
6.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Retail pharmacies
6.1.2.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Online pharmacies
6.1.3.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Parkinson’s disease Treatment Market Overview, By Patient Care Setting, 2015 - 2027(USD Million)
7.1. Global Parkinson’s disease Treatment Market Share, By Patient Care Setting, 2015 - 2027 (USD Million)
7.1.1. Hospitals
7.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
7.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
7.1.2. Clinics
7.1.2.1. Market Type and Projections, 2015 - 2027 (USD Million)
7.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 8. Global Parkinson’s disease Treatment Market Overview, By Geography, 2015 - 2027(USD Million)
8.1. Global Parkinson’s disease Treatment Market Share, By Geography, 2015 - 2027(USD Million)
8.1.1. Market Type and projections, by Countries, 2015 - 2027 (USD Million)
8.1.2. Market Share and CAGR Comparison, by Countries, 2020 - 2027 (%)
Chapter 9. North America Parkinson’s disease Treatment Market Overview, By Countries, 2015 - 2027(USD Million)
9.1. North America Parkinson’s disease Treatment Market Overview, 2015 - 2027 (USD Million)
9.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.2. North America Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.3. North America Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.4. North America Parkinson’s disease Treatment Market Overview, By Patient Care Setting, 2015 - 2027 (USD Million)
9.1.5. North America Parkinson’s disease Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.5.1. U.S. Parkinson’s disease Treatment Market Overview, 2015 - 2027 (USD Million)
9.1.5.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.5.1.2. U.S. Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.5.1.3. U.S. Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.5.1.4. Other Segment
9.1.5.2. Canada Parkinson’s disease Treatment Market Overview, 2015 - 2027 (USD Million)
9.1.5.2.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.5.2.2. Canada Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.5.2.3. Canada Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.5.2.4. Other Segment
9.1.5.3. Mexico Parkinson’s disease Treatment Market Overview, 2015 - 2027 (USD Million)
9.1.5.3.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.5.3.2. Mexico Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.5.3.3. Mexico Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.5.3.4. Other Segment
Chapter 10. Europe Parkinson’s disease Treatment Market Overview, By Countries, 2015 - 2027(USD Million)
10.1. Europe Parkinson’s disease Treatment Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.2. Europe Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.3. Europe Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
10.1.4. Europe Parkinson’s disease Treatment Market Overview, By Patient Care Setting,2015 - 2027 (USD Million)
10.1.5. Europe Skin Care Types Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.5.1. Germany
10.1.5.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.1.2. Germany Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
10.1.5.1.3. Germany Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027(USD Million)
10.1.5.1.4. Other Segments
10.1.5.2. France
10.1.5.2.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.2.2. France Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
10.1.5.2.3. France Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027(USD Million)
10.1.5.2.4. Other Segments
10.1.5.3. UK
10.1.5.3.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.3.2. UK Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
10.1.5.3.3. UK Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027(USD Million)
10.1.5.3.4. Other Segments
10.1.5.4. Italy
10.1.5.4.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.4.2. Italy Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
10.1.5.4.3. Italy Parkinson’s disease Treatment Market Overview, By Distribution Channel 2015 - 2027(USD Million)
10.1.5.4.4. Other Segments
10.1.5.5. Spain
10.1.5.5.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.5.2. Spain Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
10.1.5.5.3. Spain Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027(USD Million)
10.1.5.5.4. Other Segments
10.1.5.6. Rest of Europe
10.1.5.6.1. Market Type and projections, 2015 – 2027
10.1.5.6.2. Rest of Europe Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
10.1.5.6.3. Rest of Europe Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027(USD Million)
10.1.5.6.4. Other Segments
Chapter 11. Asia Pacific Parkinson’s disease Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Asia Pacific Parkinson’s disease Treatment Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.2. Asia Pacific Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.3. Asia Pacific Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
11.1.4. Asia Pacific Parkinson’s disease Treatment Market Overview, By Patient Care Setting,2015 - 2027 (USD Million)
11.1.5. Asia Pacific Parkinson’s disease Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.5.1. India
11.1.5.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.5.1.2. India Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
11.1.5.1.3. India Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
11.1.5.1.4. Other Segments
11.1.5.2. China
11.1.5.2.1. Market Type and projections, 2015 - 2027(USD Million)
11.1.5.2.2. China Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
11.1.5.2.3. China Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
11.1.5.2.4. Other Segments
11.1.5.3. Japan
11.1.5.3.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.5.3.2. Japan Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
11.1.5.3.3. Japan Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027(USD Million)
11.1.5.3.4. Other Segments
11.1.5.4. South Korea
11.1.5.4.1. Market Type and projections, 2015 - 2027(USD Million)
11.1.5.4.2. South Korea Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
11.1.5.4.3. South Korea Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
11.1.5.4.4. Other Segments
11.1.5.5. Rest of Asia Pacific
11.1.5.5.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.5.5.2. Rest of Asia Pacific Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027(USD Million)
11.1.5.5.3. Rest of Asia Pacific Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
11.1.5.5.4. Other Segments
Chapter 12. Middle East & Africa Parkinson’s disease Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. Middle East & Africa Parkinson’s disease Treatment Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.2. Middle East & Africa Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.3. Middle East & Africa Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
12.1.4. Middle East & Africa Parkinson’s disease Treatment Market Overview, By Patient Care Setting,2015 - 2027 (USD Million)
12.1.5. Middle East & Africa Parkinson’s disease Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1.5.1. GCC
12.1.5.1.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.5.1.2. GCC Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.5.1.3. GCC Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
12.1.5.1.4. Other Segments
12.1.5.2. South Africa
12.1.5.2.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.5.2.2. South Africa Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.5.2.3. South Africa Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
12.1.5.2.4. Other Segments
12.1.5.3. Rest of Middle East & Africa
12.1.5.3.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.5.3.2. Rest of Middle East & Africa Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.5.3.3. Rest of Middle East & Africa Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
12.1.5.3.4. Other Segments
Chapter 13. South America Parkinson’s disease Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
13.1. South America Parkinson’s disease Treatment Market Overview, 2015 - 2027 (USD Million)
13.1.1. Market Type and projections, 2015 - 2027 (USD Million)
13.1.2. South America Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
13.1.3. South America Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
13.1.4. South America Parkinson’s disease Treatment Market Overview, By Patient Care Setting,2015 - 2027 (USD Million)
13.1.5. South America Parkinson’s disease Treatment Market Overview, By Countries, 2015- 2026 (USD Million)
13.1.6. Brazil
13.1.6.1. Market Type and projections, 2015 - 2027 (USD Million)
13.1.6.2. Brazil Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
13.1.6.3. Brazil Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
13.1.6.4. Other Segments
13.1.7. Argentina
13.1.7.1. Market Type and projections, 2015 - 2027 (USD Million)
13.1.7.2. Argentina Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
13.1.7.3. Argentina Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
13.1.7.4. Other Segments
13.1.8. Rest of South America
13.1.8.1. Market Type and projections, 2015 – 2027
13.1.8.2. Rest of South America Parkinson’s disease Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
13.1.8.3. Rest of South America Parkinson’s disease Treatment Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
13.1.8.4. Other Segments
Chapter 14. Competitive Landscape
14.1. Competitive environment, 2021
14.2. Strategic framework
14.2.1. Partnership/agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New Type development
Chapter 15. Key Vendor Analysis
15.1. Teva
15.1.1. Company overview
15.1.2. Financial performance
15.1.3. Product Benchmarking
15.1.4. Recent initiatives
15.1.5. SWOT analysis
15.2. Novartis AG
15.2.1. Company overview
15.2.2. Financial performance
15.2.3. Product Benchmarking
15.2.4. Recent initiatives
15.2.5. SWOT analysis
15.3. GSK
15.3.1. Financial performance
15.3.2. Product Benchmarking
15.3.3. Recent initiatives
15.4. AbbVie
15.5. Merck
15.6. Boehringer Ingelheim
15.7. Impax Laboratories
15.8. UCB
15.9. Others
Chapter 16. Parkinson’s disease Treatment Market Cost Analysis
16.1. Parkinson’s disease Treatment Market Key Type Analysis
16.1.1. Key Type
16.1.2. Price Trend of Key Type
16.1.3. Key Suppliers of Type
16.1.4. Market Concentration Rate of Type
16.1.5. Labor Cost
Chapter 17. Sourcing Strategy and Downstream Buyers
17.1. Parkinson’s disease Treatment Market Industrial Chain Analysis
17.2. Upstream Type Sourcing
17.3. Parkinson’s disease Treatment Market Major Manufacturers in 2021
17.4. Downstream Buyers
Chapter 18. Marketing Strategy Analysis, Distributors/Traders
18.1. Marketing Channel
18.1.1. Direct Marketing
18.1.2. Indirect Marketing
18.1.3. Marketing Channel Development Trend
18.2. Market Positioning
18.2.1. Pricing Strategy
18.2.2. Brand Strategy
18.2.3. Target Client
18.3. Distributors/Traders List
Chapter 19. Market Effect Factors Analysis
19.1. Technology Progress/Risk
19.1.1. Substitutes Threat
19.1.2. Technology Progress in Related Type
19.2. Consumer Needs/Customer Preference Change
19.3. Economic/Political Environmental Change
Chapter 20. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Parkinson’s disease Treatment Market share, By Drug Class, 2020 & 2027 (%)
10. Global Parkinson’s disease Treatment Market share, by Carbidopa/levodopa, By Drug Class, 2015 - 2027 (USD Million)
11. Global Parkinson’s disease Treatment Market share, by Dopamine receptor agonists, By Drug Class, 2015 - 2027 (USD Million)
12. Global Parkinson’s disease Treatment Market share, by MAO-inhibitors, By Drug Class, 2015 - 2027 (USD Million)
13. Global Parkinson’s disease Treatment Market share, by Others, By Drug Class, 2015 - 2027 (USD Million)
14. Global Parkinson’s disease Treatment Market share, By Distribution Channel, 2020 & 2027 (%)
15. Global Parkinson’s disease Treatment Market share, by Hospital pharmacies, By Distribution Channel, 2015 - 2027 (USD Million)
16. Global Parkinson’s disease Treatment Market share, by Retail pharmacies, By Distribution Channel 2015 - 2027 (USD Million)
17. Global Parkinson’s disease Treatment Market share, by Online pharmacies, By Distribution Channel 2015 - 2027 (USD Million)
18. Global Parkinson’s disease Treatment Market share, By Patient Care Setting, 2020 & 2027 (%)
19. Global Parkinson’s disease Treatment Market share, by Hospitals, By Patient Care Setting, 2015 - 2027 (USD Million)
20. Global Parkinson’s disease Treatment Market share, by Clinics, By Patient Care Setting 2015 - 2027 (USD Million)
21. Global Parkinson’s disease Treatment Market share, by region, 2020 & 2027 (%)
22. Global Parkinson’s disease Treatment Market share, by region, 2015 - 2027(USD Million)
23. North America Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
24. North America Parkinson’s disease Treatment Market share, by Countries, 2020 & 2027 (%)
25. U.S. Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
26. Canada Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
27. Mexico Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
28. Europe Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
29. Europe Parkinson’s disease Treatment Market share, by Countries, 2020 & 2027 (%)
30. Spain Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
31. UK Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
32. Italy Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
33. Germany Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
34. France Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
35. Rest of Europe Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
36. Asia-Pacific Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
37. Asia-Pacific Parkinson’s disease Treatment Market share, by Countries, 2020 & 2027 (%)
38. China Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
39. India Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
40. Australia Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
41. Japan Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
42. Rest of Asia-Pacific Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
43. Middle East & Africa Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
44. Middle East & Africa Parkinson’s disease Treatment Market share, by Countries, 2020 & 2027 (%)
45. GCC Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
46. South Africa Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
47. Rest Of Middle East & Africa Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
48. South America Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
49. Brazil Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
50. Mexico Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
51. Argentina Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
52. Rest Of South America Parkinson’s disease Treatment Market, 2015 - 2027(USD Million)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Parkinson’s disease Treatment Market, 2015-2027 (USD Million)
4. Parkinson’s disease Treatment requirement, by country, 2015-2027, (USD Million)
5. North America Parkinson’s disease Treatment Market, By Drug Class, 2015-2027 (USD Million)
6. North America Parkinson’s disease Treatment Market, By Distribution Channel, 2015-2027 (USD Million)
7. North America Parkinson’s disease Treatment Market, By Patient Care Setting, 2015-2027 (USD Million)
8. Europe Parkinson’s disease Treatment Market, By Drug Class, 2015-2027 (USD Million)
9. Europe Parkinson’s disease Treatment Market, By Distribution Channel, 2015-2027 (USD Million)
10. Europe Parkinson’s disease Treatment Market, By Patient Care Setting, 2015-2027 (USD Million)
11. Asia Pacific Parkinson’s disease Treatment Market, By Drug Class, 2015-2027 (USD Million)
12. Asia Pacific Parkinson’s disease Treatment Market, By Distribution Channel, 2015-2027 (Revenue, USD Million)
13. Asia Pacific Parkinson’s disease Treatment Market, By Patient Care Setting, 2015-2027 (Revenue, USD Million)
14. Middle East & Africa Parkinson’s disease Treatment Market, By Drug Class, 2015-2027 (USD Million)
15. Middle East & Africa Parkinson’s disease Treatment Market, By Distribution Channel, 2015-2027 (USD Million)
16. Middle East & Africa Parkinson’s disease Treatment Market, By Patient Care Setting, 2015-2027 (USD Million)
17. South America Parkinson’s disease Treatment Market, By Drug Class, 2015-2027 (USD Million)
18. South America Parkinson’s disease Treatment Market, By Distribution Channel, 2015-2027 (USD Million)
19. South America Parkinson’s disease Treatment Market, By Patient Care Setting, 2015-2027 (USD Million)
20. Global Parkinson’s disease Treatment Market, Company Market Share, 2020 - 2027 (%)
21. Teva : Product Benchmarking
22. Teva : Financial Performance
23. Novartis AG: Product Benchmarking
24. Novartis AG: Financial Performance
25. GSK : Product Benchmarking
26. GSK : Financial Performance
27. AbbVie : Product Benchmarking
28. AbbVie : Financial Performance
29. Merck : Product Benchmarking
30. Merck : Financial Performance
31. Boehringer Ingelheim : Product Benchmarking
32. Boehringer Ingelheim : Financial Performance
33. Impax Laboratories : Product Benchmarking
34. Impax Laboratories : Financial Performance
35. UCB : Product Benchmarking
36. UCB : Financial Performance
The Leading Key Players in Parkinsons Disease Treatment Market
Teva (Israel)
Novartis AG (Switzerland)
GSK (UK)
AbbVie (US)
Merck (US)
Boehringer Ingelheim (Germany)
Impax Laboratories (US)
Lundbeck (Denmark)
UCB (Belgium)
Valeant Pharmaceuticals (Canada)
Acadia (US)
Sun Pharma (India)
Wockhardt (India)
Dr. Reddy’s (India)
Intas (India)
US WorldMeds (US)
Zydus Cadila (India)
Cipla (India)
Strides (India)
1 A Pharma (India)
Upsher-Smith (US).
